{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:30:39Z","timestamp":1792153839861,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jtho.2023.03.004","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T15:25:48Z","timestamp":1684423548000},"page":"678-681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Systemic Treatment for Brain Metastases in NSCLC: A New Chapter"],"prefix":"10.1016","volume":"18","author":[{"given":"Fabian","family":"Acker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike C.","family":"Althoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2023.03.004_bib1","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","article-title":"Non-small-cell lung cancer with brain metastasis at presentation","volume":"19","author":"Waqar","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2023.03.004_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.03.004_bib3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.03.004_bib4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00000421-199912000-00007","article-title":"Late radiation toxicity after whole-brain radiotherapy: the influence of antiepileptic drugs","volume":"22","author":"Nieder","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtho.2023.03.004_bib5","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO\u2013ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours\u2606","volume":"32","author":"Rhun","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2023.03.004_bib6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jtho.2023.01.083","volume":"18","author":"Hou","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.03.004_bib7","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407","volume":"16","author":"Powell","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.03.004_bib8","article-title":"Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042","volume":"2","author":"Mansfield","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2023.03.004_bib9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","article-title":"First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations","volume":"18","author":"Paz-Ares","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.03.004_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2018.12.025","article-title":"Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer","volume":"129","author":"Crin\u00f2","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2023.03.004_bib11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","article-title":"Outcome of patients with non\u2013small cell lung cancer and brain metastases treated with checkpoint inhibitors","volume":"14","author":"Hendriks","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 16","key":"10.1016\/j.jtho.2023.03.004_bib12","article-title":"Updated analysis from the ATEZO-BRAIN trial: atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non\u2013small cell lung cancer with untreated brain metastases","volume":"40","author":"Nadal","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.03.004_bib13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.03.004_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.03.004_bib15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.03.004_bib16","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.03.004_bib17","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-21-1046","article-title":"Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases","volume":"27","author":"Di Giacomo","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2023.03.004_bib18","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.wneu.2019.04.031","article-title":"Worldwide access to stereotactic radiosurgery","volume":"130","author":"Pannullo","year":"2019","journal-title":"World Neurosurg"},{"key":"10.1016\/j.jtho.2023.03.004_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10585-019-10005-2","article-title":"Disparities in the use of stereotactic radiosurgery for the treatment of lung cancer brain metastases: a SEER-Medicare study","volume":"37","author":"Ascha","year":"2020","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.jtho.2023.03.004_bib20","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 7","key":"10.1016\/j.jtho.2023.03.004_bib21","doi-asserted-by":"crossref","first-page":"S992","DOI":"10.1016\/j.annonc.2022.07.1101","article-title":"973MO KEYNOTE-189 5-year update: first-line pembrolizumab (pembro)\u00a0+ pemetrexed (pem) and platinum vs placebo (pbo)\u00a0+ pem and platinum for metastatic nonsquamous NSCLC","volume":"33","author":"Garassino","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jtho.2023.03.004_bib22","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2023.03.004_bib23","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non\u2013small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.03.004_bib24","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.03.004_bib25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non\u2013small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.03.004_bib26","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/annonc\/mdu584","article-title":"A\u00a0randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2023.03.004_bib27","doi-asserted-by":"crossref","first-page":"8489","DOI":"10.2147\/CMAR.S341287","article-title":"Phase II study of nivolumab plus ipilimumab with platinum-based chemotherapy for treatment-na\u00efve advanced non-small cell lung cancer with untreated brain metastases: Nike trial (LOGiK2004)","volume":"13","author":"Tsuchiya-Kawano","year":"2021","journal-title":"Cancer Manag Res"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423001909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423001909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:51:53Z","timestamp":1761562313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086423001909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1556086423001909"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2023.03.004","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Treatment for Brain Metastases in NSCLC: A New Chapter","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2023.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}